Prothena Stock News

Nikola Corp. has signed a multiyear deal with battery maker Proterra Inc. to use Proterra battery packs in its electric trucks. It is the first Class 8 truck maker to align with Proterra Powered, a ne

On CNBC’s "Mad Money Lightning Round," Jim Cramer said ChargePoint Holdings, Inc. (NYSE: CHPT) is "part of a very challenged group." Following a deep research on the group, he added that there are

On CNBCs "Mad Money Lightning Round," Jim Cramer said ChargePoint Holdings, Inc. (NYSE: CHPT ) is "part of a very challenged group." Following a deep research on the group, he added that there are several players and there has "not been enough consolidation." He recommended avoiding the stock. Cramer said he likes Prothena Corporation plc (NASDAQ: PRTA ) as it has a very positive Alzheimers formulation and other things Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio Therapeutics, Inc. (NASD

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplar

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplar

Brokerages expect Prothena Co. plc (NASDAQ:PRTA) to announce earnings per share of ($0.71) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Prothena’s earnings, with the highest EPS estimate coming in at ($0.52) and the lowest estimate coming in at ($0.84). Prothena reported earnings per share of ($0.77) in the […]

These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Prothena has a drug candidate Birtamimab in phase three trials and is close to approval. The company has a promising pipeline in some high-revenue neurodegenerative disease fields.

DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built o

DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built

DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday December 6, 2021 at 1:20 PM ET.

Wall Street brokerages forecast that Prothena Co. plc (NASDAQ:PRTA) will report earnings per share of ($0.71) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Prothenas earnings. The lowest EPS estimate is ($0.84) and the highest is ($0.52). Prothena reported earnings of ($0.77) per share in the same quarter last []